SynopsisRadicava is an intravenous medication used to help with recovery following a stroke[1] and to treat amyotrophic lateral sclerosis (ALS). The global Radicava market was valued at US$ 246 million in 2023 and is anticipated to reach US$ 496 million by 2030,.....
SynopsisEdaravone, sold as under the brand names Radicava and Radicut, is an intravenous medication used to help with recovery following a stroke[1] and to treat amyotrophic lateral sclerosis (ALS). The global Edaravone Injection market was valued at US$ 246 mil.....
SynopsisRadicut is an intravenous medication used to help with recovery following a stroke[1] and to treat amyotrophic lateral sclerosis (ALS). The global Radicut market was valued at US$ 246 million in 2023 and is anticipated to reach US$ 496 million by 2030, w.....
SynopsisRilutek is a drug used to treat amyotrophic lateral sclerosis. The global Rilutek market was valued at US$ 40 million in 2023 and is anticipated to reach US$ 38 million by 2030, witnessing a CAGR of -1.2% during the forecast period 2024-2030. The a.....
SynopsisRiluzole (marketed as Rilutek, Teglutik and TIGLUTIK) is a drug used to treat amyotrophic lateral sclerosis. The global Riluzole Tablet market was valued at US$ 40 million in 2023 and is anticipated to reach US$ 38 million by 2030, witnessing a CAGR of -.....
SynopsisTeglutik is a drug used to treat amyotrophic lateral sclerosis. The global Teglutik market was valued at US$ 40 million in 2023 and is anticipated to reach US$ 38 million by 2030, witnessing a CAGR of -1.2% during the forecast period 2024-2030. The.....
SynopsisTIGLUTIK is a drug used to treat amyotrophic lateral sclerosis. The global TIGLUTIK market was valued at US$ 40 million in 2023 and is anticipated to reach US$ 38 million by 2030, witnessing a CAGR of -1.2% during the forecast period 2024-2030. The.....
SynopsisAmyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. The cause is not known in 90% to 95% of cases. The remaining 5–10% of c.....
SynopsisAnaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma (NHL), and one of the subtypes of T-cell lymphoma. The global Anaplastic Large Cell Lymphoma Drugs market was valued at US$ 1243 million in 2023 and is anticipated to reach US$ .....
SynopsisAdcetris is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lympho.....
